New Jersey employers continue to remain without meaningful guidance on the issue of how they may legally maintain a drug-free workplace. On February 22, 2021, the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization... Read More
On January 12, 2022, the Centers for Medicare and Medicaid Services (“CMS”) issued a proposed new rule (the “Rule”) which, among other things, may fundamentally change controversial Direct and Indirect Remuneration (“DIR”) fees about... Read More
Independent pharmacies in Texas have significant protections from unfair practices by Pharmacy Benefit Managers (PBMs) in the form of HB 1919 and HB 1763. As previously discussed by Frier Levitt, HB 1763 provides Texas pharmacies with safeguards... Read More
Since going into effect on October 1, 2021, North Carolina Senate Bill 257 (SB 257) has provided independent pharmacies with significant protections against unfair PBM conduct and improved the landscape for pharmacies in North Carolina. The most... Read More
With the new year here, so come new challenges for independent pharmacies. But in addition to new challenges, there is also good reason for independent pharmacies to be optimistic about opportunities ahead and solutions to some of the challenges... Read More
Frier Levitt attorney Abdul J. Roberts and HealthCare Compliance Network’s Director of Coding and Billing Compliance Jim Tudor discuss recent trends in medical audits and what physicians can expect in their article in Medical Economics, titled,... Read More
Frier Levitt Attorney Lawrence F. Kobak's article, "OSHA, the Exposure Control Plan, and the Podiatry Practice," was published in the January 2022 edition of Podiatry Management. Read the full article... Read More
On December 16, 2021, the Department of Health and Human Services, Office of Inspector General (“OIG”) issued a report analyzing nationwide trends in genetic tests for which payments were made under Medicare Part B. The OIG report follows a... Read More
New Jersey’s Acting Attorney General, Andrew J. Bruck, recently announced the largest enforcement action against fifteen companies across several industries for their unlawful hiring practices in violation of New Jersey’s Opportunity to Compete... Read More
In the patent infringement case Amarin v Hikma, the plaintiffs, a biopharmaceutical company, alleged induced patent infringement against both the generic manufacturer for its skinny label not carving out the patented indications sufficiently and the... Read More
